drugset / Trial / NCT05674045
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence
Phase 2
Completed
51 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Peking University People's Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether EG017 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
Timeline
- Start
- 2022-01-06
- Primary completion
- 2022-01-06
- Completion
- 2022-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EG017 | Unknown | 3 mg | Oral |
| Subject | EG017 | Unknown | 6 mg | Oral |